https://clinicaltrials.gov/ct2/show/NCT02195349
The above link is regarding the GSK phase1 trial of our lag3 product. The above was released in December ‘17.
It’s fully recruited and to me it looks like the trial ends in March this year.
Interesting thing here is that the new CEO of GSK ordered a cul of products under trial last year , but our product in phase1 survived the cul.
Must have shown positive progress .
O/N Nasdaq, page-190
-
- There are more pages in this discussion • 440 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
0.005(1.39%) |
Mkt cap ! $530.2M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.0¢ | 36.0¢ | $445.1K | 1.222M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 170533 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 456242 | 40 |
View Market Depth
| Last trade - 14.00pm 22/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |